Abstract
Cancer immunotherapy is expected to be the fourth treatment against cancer. OK-432 (Picibanil®), which is dry mycelia of hemolytic streptococcus, PSK (Krestin®), which is a protein-bound polysaccharide obtained from basidiomycetes, and Lentinan®, which is polysaccharide from shiitake, are administered as anti-cancer agents. However, even when administered, patients only gain increased non-specific immunity; there is no selective attack on cancer cells. On the other hand, the peptide vaccine, which we started as a new medication for cancer vaccine therapy in this study, increases only specific anti-tumor lymphocytes which can attack only cancer cells very selectively. We report on our cancer peptide vaccine therapy against oral cancer.
